```json
{
"content": [
{
"type": "paragraph",
"content": "The hearing loss therapy segmentation by application distinguishes five primary categories that collectively drive the market’s revenue composition. Hearing aids remain the dominant application, accounting for roughly 45 % of total sales, reflecting their broad adoption across mild to moderate sensorineural loss and the mature global distribution network. Cochlear implants represent the second‑largest share at about 30 %, propelled by expanding candidacy criteria and reimbursement improvements in emerging economies. Pharmacotherapy, encompassing systemic and intratympanic drug delivery, contributes an estimated 15 % as research advances toward disease‑modifying agents. Gene‑therapy approaches, still early‑stage but rapidly scaling, hold a 5 % share, driven by clinical trials targeting hereditary forms of deafness. Assistive listening devices, including FM systems and Bluetooth streamers, also occupy roughly 5 % of the market, primarily serving niche environments such as classrooms and workplaces. Together, these application segments define the overall hearing loss therapy market size and inform strategic investment priorities. The proportional weighting of each segment also shapes R&D allocation and pricing dynamics across the industry."
},
{
"type": "paragraph",
"content": "Within the hearing loss therapy market taxonomy, the Types dimension disaggregates each application into relevant sub‑categories that influence product development cycles and reimbursement pathways. Hearing‑aid types include behind‑the‑ear (BTE), in‑the‑ear (ITE) and receiver‑in‑canal (RIC) devices
